LOGIN
Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma
June 2022
Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial
Adv Clin Exp Med. 2022 01-Mar;():. 10.17219/acem/142332Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
200 pediatric osteosarcoma patients were randomized to receive a single intravenous dose of palonosetron or granisetron for antiemetic prophylaxis. The primary outcome was patient response to treatment in the first 24 hours after chemotherapy (complete response; partial response; failure). Adverse events were also recorded. Results found that patients who received palonosetron had a significantly ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.